Pacific Biosciences Q2 2024 Adj. EPS $(0.20) Beats $(0.23) Estimate, Sales $36.013M Miss $40.878M Estimate
Portfolio Pulse from Benzinga Newsdesk
Pacific Biosciences (NASDAQ:PACB) reported Q2 2024 adjusted EPS of $(0.20), beating the estimate of $(0.23). However, sales of $36.013M missed the $40.878M estimate and were down 24.30% year-over-year.
August 07, 2024 | 8:53 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Pacific Biosciences reported better-than-expected EPS of $(0.20) for Q2 2024, but sales missed estimates and were down significantly year-over-year.
While the EPS beat is a positive sign, the significant miss on sales and the year-over-year decline in revenue are concerning. This mixed result is likely to result in neutral short-term price movement as investors weigh the positive EPS against the negative sales performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100